FDA Updates Contraindications for Myrbetriq
The U.S. Food and Drug Administration (FDA) has updated the label on Myrebetriq to include a new contraindication and additional information in the Warnings and Precautions section. The revised label now states that the drug, which is used to treat an overactive bladder, is contraindicated in patients who are hypersensitive to … [Read more...]
Actos Bladder Cancer Warning
Actos Bladder Cancer Warning. Doctors and patients in Canada have been warned that taking Actos for more than a year may increase the risk of developing bladder cancer. In an alert issued last month, Health Canada said that Takeda Pharmaceuticals, the maker of Actos, had agreed to update the drug's Canadian label to warn of … [Read more...]
Approved Epilepsy Drugs Suicide Warnings
Epilepsy Drugs May Cause Suicidal Thoughts. Federal regulators have approved new suicide warnings for more than two dozen epilepsy drugs. The Food & Drug Administration (FDA) had ordered the label update last December, when it issued a public-health advisory regarding the association between epilepsy drugs and suicidal … [Read more...]